HLS Therapeutics Announces Q1 2024 Financial Results

TORONTO, May 9, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three-month period ended March 31, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

KEY HIGHLIGHTS

• Q1 2024 revenue was $12.5 million, Adjusted EBITDA¹ was $2.7 million and cash from operations was $0.8 million, compared to $14.8 million, $5.1 million and $4.0 million, respectively, in Q1 2023.
• Canadian product sales grew 4% from $8.8 million to $9.2 million, however, royalty revenues declined 75% from $2.7 million to $0.7 million.
• Completed a Product Listing Agreement ("PLA") with the province of British Columbia ("BC"), for the listing and public reimbursement of Vascepa.  
• On May 1, 2024, HLS provided Pfizer with a notice of termination of the promotional services agreement (the "Agreement") for the commercialization of Vascepa in primary care.

"We made progress on several fronts in Q1, but financial results for Vascepa and Clozaril were below expectations as ex-factory orders typically placed at quarter end were pushed into April due to the early Easter holiday. As expected, the large decline in royalty related revenue had the greatest impact on revenue and Adjusted EBITDA," said Craig Millian, CEO of HLS. "Subsequent to quarter end, we saw a pick-up in activity as Canadian ex-factory sales for Vascepa and Clozaril grew 25% year-over-year in April as compared to March, which had a 3% year-over-year decline."

Q1 2024 OTHER HIGHLIGHTS

• Vascepa unit demand increased by 54% compared to Q1 2023.
• The number of consistent prescribers² for Vascepa increased 112% compared to Q1 2023.
• Vascepa net revenue was C$4.5 million, up 27% compared to C$3.5 million in Q1 2023. 
• The number of patients on Clozaril in Canada increased by 1.4% compared to Q1 2023.

Mr. Millian added: "Following a solid start to the year for Vascepa in January and February, March unit demand and sales activity fell short of expectations. Although sales growth picked up in April, unit demand is still tracking below the 70% full-year target that is needed to get us back to plan.  While we are confident that several catalysts will help drive demand growth this year, including the public listing in BC, we have concluded that Vascepa is unlikely to achieve its full year sales goal. Therefore, bold action is required to meet our objective of getting Vascepa to profitability by year end."

"We have been closely examining the performance of our go-to-market model in primary care. We have concluded that the ROI for this model remains unprofitable and, despite best efforts, there are not enough signs of improvement to justify continuing at our current level of investment. As a result, we have provided Pfizer with a notice of termination of the Agreement between the two companies. We are working with them on an orderly wind down and transition back to HLS of all primary care related activities which we expect will be completed during the second half of 2024. We thank Pfizer for the commitment and effort that they have made towards trying to make this go-to-market model successful."

"We believe in the promise and long-term revenue potential of Vascepa and are confident we can effectively support both specialists and the growing base of primary care prescribers with our HLS sales team while retaining the flexibility to scale the team as demand grows. We are excited about this opportunity to bring both specialty and primary care in-house and to take an even greater role in ensuring this important medicine reaches its potential. Furthermore, the termination of the Agreement with Pfizer, once fully executed, could result in as much as $5 million in annual OPEX savings. Ultimately, we are committed to getting Vascepa to profitability by year-end and are confident we can continue to drive growth at a reasonable cost. Positioning Vascepa to be a positive contributor to Adjusted EBITDA by year end sets up well for long-term profitable growth given that its patent estate extends into the 2030s, with the last patent set to expire in 2039."

2024 UPDATED OUTLOOK

For both Vascepa and Clozaril, HLS expects to positively impact demand for the remainder of the year with the actions it is taking. However, based on year-to-date trends for Vascepa and some potential adjustments from the sales force transition, the Company is lowering its full year consolidated revenue guidance to a range of $60-62 million from $63.5-66.5 million. 

Vascepa revenue is now expected to be in a range of $17-18 million (C$22.5-24.5 million), compared to the prior range of $20.5-22.5 million (C$27.5-30 million). The revised 2024 Vascepa revenue guidance represents an increase of 27-38% over 2023. Clozaril demand trends are in line with expectations through April and it remains on track with its 2024 revenue outlook of about $40 million. The 2024 outlook for the royalty portfolio also remains unchanged with it expected to generate revenue of $3-4 million.

Based on lower expected sales of Vascepa, and not including any potential benefits the Company may derive in 2024 from the termination of the Agreement described above, HLS is also lowering its full year Adjusted EBITDA target to $17-19 million from its prior expectation of $21 million. The Company will continue to identify expense reductions and still expects Vascepa to make a positive contribution to Adjusted EBITDA starting in the fourth quarter.

Q1 2024 FINANCIAL REVIEW

The Company's Management's Discussion and Analysis and Consolidated Financial Statements for the three-month period ended March 31, 2024, are available at the Company's website and at its profile at SEDAR+.

Revenue

			Three months ended March 31,
			2024	2023
Product sales
Canada			9,154	8,811
United States			2,642	3,212
			11,796	12,023
Royalty revenue			677	2,734
			12,473	14,757

Excluding royalties, revenue for the Company's marketed products (Vascepa, and Clozaril) in Q1 2024 was down 2% from Q1 2023. Lower than expected sales were driven in large part by the delayed timing of ex-factory orders for both Vascepa and Clozaril at the end of March and, in the case of US Clozaril, excess year-end inventory.

Product sales – Canada

000's of CAD				Three months ended March 31,
				2024	2023	% change
Clozaril				7,865	8,418	(6.6) %
Vascepa				4,471	3,515	27.2 %
Other				13
				12,349	11,933	3.5 %

Q1 2024 product sales in Canada increased 3.5% in Canadian dollars compared to Q1 2023. This was led by growth in Canadian dollar sales of Vascepa, which increased 27% in Q1 2024, while Q1 2024 Clozaril revenue in Canada declined 7% compared to Q1 2023. The last week of the quarter overlapped with the Easter holiday weekend, which resulted in certain orders typically placed during the final business days of Q1 2024 being pushed into the first week of April.  The timing of orders negatively impacted both Vascepa and Clozaril net sales by a combined total exceeding US$0.6 million. Reflecting strong underlying demand fundamentals, patient numbers for Clozaril Canada were up 1.4% in Q1 2024 compared to Q1 2023.

Product Sales – United States

In the U.S., Q1 2024 Clozaril sales declined 18% compared to Q1 2023. Key demand fundamentals remain in place with the variance to the prior year revenue largely due to wholesalers in the US ending 2023 with an unusually high level of inventory and subsequently working through that in Q1 2024.

Royalty revenues

Q1 2024 royalty revenues were down 75% from Q1 2023 as the term for what was the largest royalty in the portfolio came to an end midway through Q4 2023.

Operating Expenses

			Three months ended March 31,
			2024	2023
Cost of product sales			1,774	1,444
Selling and marketing			4,526	4,807
Medical, regulatory and patient support			1,265	1,076
General and administrative			2,201	2,351
			9,766	9,678

Cost of product sales was up for the quarter due to the higher sales volumes of Vascepa.

Excluding cost of product sales, Q1 2024 operating expenses were $8.0 million, down 3% from Q1 2023. Selling and marketing and general and administrative expenses were both down by 6% compared to Q1 2023, while medical, regulatory and patient support expenses increased 18% due to timing differences for expense recognition but is expected to be similar overall in 2024 to the prior year. For 2024, the Company will continue to focus on cost management and seeking expense reductions throughout the business.

Adjusted EBITDA¹

			Three months ended March 31,
			2024	2023
Net loss for the period			(6,106)	(5,792)
Stock-based compensation			256	(55)
Amortization and depreciation			5,919	8,319
Finance and related costs, net			2,667	2,434
Other costs			—	213
Income tax recovery			(29)	(40)
Adjusted EBITDA			2,707	5,079

Q1 2024 Adjusted EBITDA was $2.7 million compared to $5.1 million in Q1 2023. The decrease for the quarter was due primarily to the 75% decrease in royalty portfolio revenue as well as the timing of certain Clozaril and Vascepa orders during the quarter, which was partially offset by the 27% growth in Vascepa revenue.  

For Q1 2024, the direct brand contribution from Clozaril to Adjusted EBITDA was $6.1 million, while the direct brand contribution from Vascepa to Adjusted EBITDA was a loss of $1.6 million.

Net Loss

Net loss for Q1 2024 was ($6.1) million, or ($0.19) per share, compared to a net loss of ($5.8) million, or ($0.18) per share, in Q1 2023. Net loss increased in Q1 2024 primarily due to the changes to revenue and operating expenses as previously explained.

Cash from Operations and Financial Position

Cash generated from operations in Q1 2024 was $0.8 million compared to $4.0 million in Q1 2023. Cash was $19.4 million at March 31, 2024 compared to $22.0 million at December 31, 2023.

Total borrowings under the credit agreement at March 31, 2024, was $86.4 million compared to $88.5 million at December 31, 2023.

Q1 2024 CONFERENCE CALL

HLS will hold a conference call today at 8:30 am Eastern Time to discuss its Q1 2024 financial results. The call will be hosted by Mr. Craig Millian, CEO, and Mr. John Hanna, Interim CFO. To view the slides that accompany management's discussion, please use the webcast link.

CONFERENCE ID: 64428

DATE: Thursday, May 9, 2024

TIME: 8:30 a.m. ET

WEBCAST LINK: https://app.webinar.net/lw3W7LjxZGA 

TRADITIONAL DIAL-IN NUMBER: 1-800-836-8184 or 1-289-819-1350

RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3xw9YCV 

TAPED REPLAY:  1-888-660-6345 or 1-289-819-1450

REPLAY CODE: 64428#

The taped replay will be available for 14 days and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes before the conference call to ensure enough time for any software download required to hear the webcast.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

 ¹CAUTIONARY NOTE REGARDING NON-IFRS MEASURES

This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of HLS's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of HLS's financial information reported under IFRS. HLS uses non-IFRS measures to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. HLS also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. HLS's management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess HLS's ability to meet its future debt service, capital expenditure and working capital requirements.

In particular, management uses Adjusted EBITDA as a measure of HLS's performance.  To reconcile net income (loss) for the period with Adjusted EBITDA, each of (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "finance and related costs, net", (iv) "other costs", and (v) "income tax recovery" appearing in the Consolidated Statement of Net Income (Loss) are added to net income (loss) for the period to determine Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.  Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS as issued by the IASB.

²CONSISTENT PRESCRIBER

A consistent prescriber is a physician that has prescribed Vascepa in at least 4 of the past 5 weeks.

FORWARD LOOKING INFORMATION

This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 13, 2024, and Management's Discussion and Analysis dated May 8, 2024, both of which have been filed on SEDAR and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Unaudited
[in thousands of U.S. dollars]
		As at	As at
		March 31, 2024	December 31, 2023
ASSETS
Current
Cash		19,443	21,952
Accounts receivable		9,566	10,608
Inventories		10,085	9,534
Income taxes recoverable		81	86
Other current assets		1,601	1,915
Total current assets		40,776	44,095
Property, plant and equipment		824	965
Intangible assets		154,458	162,344
Deferred tax asset		1,088	1,037
Other non-current assets		605	619
Total assets		197,751	209,060
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities		13,128	14,107
Provisions		5,880	5,424
Debt and other liabilities		6,881	6,876
Income taxes payable		305	281
Total current liabilities		26,194	26,688
Debt and other liabilities		82,059	84,233
Deferred tax liability		432	442
Total liabilities		108,685	111,363
Shareholders' equity
Share capital		261,359	262,127
Contributed surplus		13,996	13,865
Accumulated other comprehensive loss		(5,211)	(2,838)
Deficit		(181,078)	(175,457)
Total shareholders' equity		89,066	97,697
Total liabilities and shareholders' equity		197,751	209,060

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS
Unaudited
[in thousands of U.S. dollars, except per share amounts]
						Three months ended March 31,
						2024		2023
Revenue						12,473		14,757
Expenses
Cost of product sales						1,774		1,444
Selling and marketing						4,526		4,807
Medical, regulatory and patient support						1,265		1,076
General and administrative						2,201		2,351
Stock-based compensation						256		(55)
Amortization and depreciation						5,919		8,319
Finance and related costs, net						2,667		2,434
Other costs						—		213
Loss before income taxes						(6,135)		(5,832)
Income tax recovery						(29)		(40)
Net loss for the period						(6,106)		(5,792)
Net loss per share:
Basic and diluted						$(0.19)		$(0.18)
HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Unaudited
[in thousands of U.S. dollars]
							Three months ended March 31,
							2024		2023
Net loss for the period							(6,106)		(5,792)
Item that may be reclassified subsequently to net loss
Unrealized foreign currency translation adjustment							(2,373)		93
Comprehensive loss for the period							(8,479)		(5,699)

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
Unaudited
[in thousands of U.S. dollars]
		Share capital	Contributed surplus	Accumulated other comprehensive loss	Deficit	Total
Balance, December 31, 2023		262,127	13,865	(2,838)	(175,457)	97,697
Shares repurchased		(768)	—	—	485	(283)
Stock option expense		—	131	—	—	131
Net loss for the period		—	—	—	(6,106)	(6,106)
Unrealized foreign currency         translation adjustment		—	—	(2,373)	—	(2,373)
Balance, March 31, 2024		261,359	13,996	(5,211)	(181,078)	89,066
Balance, December 31, 2022		265,206	13,821	(5,260)	(148,449)	125,318
Stock options exercised		178	(44)	—	—	134
Shares repurchased		(219)	—	—	35	(184)
Share purchase obligation		—	185	—	—	185
Stock option expense		—	319	—	—	319
Net loss for the period		—	—	—	(5,792)	(5,792)
Dividends declared		—	—	—	(1,182)	(1,182)
Unrealized foreign currency         translation adjustment		—	—	93	—	93
Balance, March 31, 2023		265,165	14,281	(5,167)	(155,388)	118,891

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
Unaudited
[in thousands of U.S. dollars]
		Three months ended March 31,
		2024	2023
OPERATING ACTIVITIES
Net loss for the period		(6,106)	(5,792)
Adjustments to reconcile net loss to cash provided by operating activities
Stock-based compensation		256	(55)
Amortization and depreciation		5,919	8,319
Accreted interest		282	191
Fair value adjustment on financial assets and liabilities		187	551
Deferred income taxes		(61)	(177)
Net change in non-cash working capital balances related to operations		301	983
Cash provided by operating activities		778	4,020
INVESTING ACTIVITIES
Additions to property, plant and equipment		(2)	—
Cash used in investing activities		(2)	—
FINANCING ACTIVITIES
Stock options exercised		—	134
Shares repurchased		(283)	(184)
Dividends paid		—	(1,182)
Repayment of credit agreement borrowing		(2,075)	(2,121)
Debt costs		(533)	—
Lease payments		(143)	(161)
Cash used in financing activities		(3,034)	(3,514)
Net increase (decrease) in cash during the period		(2,258)	506
Foreign currency translation		(251)	(15)
Cash, beginning of period		21,952	20,723
Cash, end of period		19,443	21,214

SOURCE HLS Therapeutics Inc.

HLS CONTACT INFORMATION, Dave Mason, Investor Relations, HLS Therapeutics Inc., [phone], [email protected]